121 related articles for article (PubMed ID: 21527182)
21. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
[TBL] [Abstract][Full Text] [Related]
22. The routine immunohistochemical evaluation in Paget disease of the nipple.
Marczyk E; Kruczak A; Ambicka A; Mularz K; Harazin-Lechowska A; Moskal J; Sokołowski A; Mituś J; Ryś J
Pol J Pathol; 2011 Dec; 62(4):229-35. PubMed ID: 22246908
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis.
Simooka H; Oyama T; Sano T; Horiguchi J; Nakajima T
Pathol Int; 2004 Aug; 54(8):595-602. PubMed ID: 15260850
[TBL] [Abstract][Full Text] [Related]
24. Clinical and biological characteristics of breast cancer.
Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
[TBL] [Abstract][Full Text] [Related]
25. Role of E-cadherins in development of lymphatic tumor emboli.
Gupta A; Deshpande CG; Badve S
Cancer; 2003 May; 97(9):2341-7. PubMed ID: 12712492
[TBL] [Abstract][Full Text] [Related]
26. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of selected immunohistochemical parameters in patients with invasive breast carcinoma concomitant with ductal carcinoma in situ.
Patla A; Rudnicka-Sosin L; Pawlega J; Stachura J
Pol J Pathol; 2002; 53(1):25-7. PubMed ID: 12014222
[TBL] [Abstract][Full Text] [Related]
28. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
29. MnSOD expression is less frequent in tumour cells of invasive breast carcinomas than in in situ carcinomas or non-neoplastic breast epithelial cells.
Soini Y; Vakkala M; Kahlos K; Pääkkö P; Kinnula V
J Pathol; 2001 Sep; 195(2):156-62. PubMed ID: 11592093
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
[TBL] [Abstract][Full Text] [Related]
32. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
Park SS; Kim JE; Kim YA; Kim YC; Kim SW
Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
[TBL] [Abstract][Full Text] [Related]
33. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
34. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
[TBL] [Abstract][Full Text] [Related]
35. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
[TBL] [Abstract][Full Text] [Related]
36. [Loss of fragile histidine triad expression and metastasis in breast cancer].
Zhao P; Li XY; Chen LZ
Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
[TBL] [Abstract][Full Text] [Related]
37. [Expression and prognostic value of transcriptional factor sp1 in breast cancer].
Wang XB; Peng WQ; Yi ZJ; Zhu SL; Gan QH
Ai Zheng; 2007 Sep; 26(9):996-1000. PubMed ID: 17927860
[TBL] [Abstract][Full Text] [Related]
38. Immunohistological localisation of human FAT1 (hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in pathogenesis?
Kwaepila N; Burns G; Leong AS
Pathology; 2006 Apr; 38(2):125-31. PubMed ID: 16581652
[TBL] [Abstract][Full Text] [Related]
39. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
40. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]